This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign ...

Nomura cited higher contribution from diabetes drug Sitaglitptin, which offers a market size of around $300-400 million to be ...

According to Report Ocean, the US Urinary Tract Infection (UTI) Therapeutics market is anticipated to grow at a CAGR of ~$% between 2022-2028 owing to rise in cases of UTIs, technological advancements ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

Ahmedabad: Zydus Lifesciences Ltd, a global healthcare company announced that it has entered into an agreement with CVS ...

Zituvimet (sitagliptin and metformin hydrochloride) and Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets.

Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...

Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd., and Fortress ...

Zydus Lifesciences announces CVS Caremark agreement and FDA priority review for diabetes and Menkes disease treatments.

Zydus Lifesciences rose 1.22% to Rs 974.75 after its wholly-owned subsidiary, Sentynl Therapeutics, and Fortress Biotech said that U.S. food and Drug Administration has accepted filing and priority ...